Torrent Pharma’s $1.38B JB Chemicals takeover; Future Pak to buy...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Torrent Pharmaceuticals will purchase roughly a 46% stake in JB...
View ArticleCloudbreak’s shares stumble in Hong Kong debut; Sinovac squares off against...
Plus, news about BrainEver, Clinigen, MaaT Pharma, Dyadic and Nektar Therapeutics: Cloudbreak Pharma shares fall in Hong Kong debut: The ophthalmology biotech, which has offices in California and...
View ArticleNovartis' Cosentyx fails Phase 3 study for autoimmune disease
Novartis faced a setback in its ambition to expand its blockbuster drug Cosentyx and compete in an autoimmune condition with products from Roche and AbbVie. The company said Thursday that the drug...
View ArticleJudge rules against Trump administration's removal of HHS web content
The Trump administration's actions to remove a broad swath of HHS webpages in late January were arbitrary and not the “product of reasoned decisionmaking,” a federal district court ruled Thursday. The
View ArticleApple Tree says its biotechs face ‘imminent collapse’; Advocates urge J&J to...
Happy July 4th weekend! We’ve got a condensed version of Endpoints Weekly for you this week, so let’s dive right into the biggest stories. First up, a key investor for Apple Tree Partners is allegedly ...
View ArticleRoche-backed Chugai taps into longevity field with Pfizer-allied Gero
Japanese drugmaker Chugai is wading into the aging-related disease landscape, an area of drug R&D that’s gaining more traction among pharmaceutical giants. The Tokyo-headquartered company, part of...
View ArticleFDA approves KalVista's HAE drug after review delay
The FDA has approved KalVista Pharmaceuticals' drug for a rare swelling disease, the company announced on Monday, in a key win for the small biopharma. The drug, called sebetralstat, will be ...
View ArticleApogee reports Phase 2 success for IL-13 drug in eczema
Apogee Therapeutics said on Monday that its atopic dermatitis candidate, which has the potential to offer a more convenient alternative to Sanofi and Regeneron's Dupixent and Eli Lilly’s Ebglyss, has...
View ArticleCompromised drug lot impacts Jasper's chronic hives study, stock falls
Jasper Therapeutics’ stock crashed on Monday morning after the biotech said issues with a drug product lot impacted data in a Phase 1b/2a clinical trial for its lead program. The specific problem isn’t...
View ArticleDenali's Hunter syndrome therapy gets priority review; LENZ inks Canada deal
Denali gets priority review for rare disease therapy: The program, called tividenofusp alfa, is designed to treat Hunter syndrome, a protein misfolding disease that begins as early as 18 months old....
View ArticleCogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial
Cogent Biosciences said it’s working on an FDA submission for its systemic mastocytosis (SM) drug after breezing through a Phase 2 trial in an indolent form of the disease. The biotech’s bezuclastinib...
View ArticleHealth tech startups raise $6.4B in first half of 2025 in AI frenzy
Investors bullish on AI have been pouring more money into digital health startups. Digital health startups in the US raised $6.4 billion across 245 deals over the first half of this year, according to...
View ArticleFDA chief calls for 'meaningful' reduction of animal testing for new drugs
FDA Commissioner Marty Makary pledged to "meaningfully reduce" unnecessary animal testing that's currently used to bring new drugs to market and to test them in early developmental stages. While...
View ArticleKalVista CEO talks FDA drug approval, review delay
The CEO of KalVista Pharmaceuticals described the behind-the-scenes discussions with FDA reviewers as "appropriate," "thorough" and "productive" in what led to an approval for its drug. The company...
View ArticleThe fight over state PBM laws will continue after Supreme Court denial
The Supreme Court recently declined to wade into a fight over a state’s regulation of pharmacy benefit managers. But legal experts say it likely won’t be the last time the broader issue makes its way ...
View ArticleTrump's tax cut law expands orphan drug exclusions, could upend 340B program
President Donald Trump on July 4 signed into law his wide-ranging tax cuts and reconciliation package, including an expansion of orphan drug protections from Medicare negotiations, and nearly $1...
View ArticleDoctors sue RFK Jr., HHS over changes to Covid-19 vaccine schedule
A group of organizations representing thousands of doctors nationwide sued HHS Secretary Robert F. Kennedy Jr. over his decision to change Covid-19 vaccine recommendations for kids and pregnant women....
View ArticleNovartis maps launch of malaria drug for newborns after Swiss approval
Novartis has secured approval in Switzerland for its malaria treatment for small babies and infants, with plans to launch the first-of-its-kind drug on a not-for-profit basis in certain regions. The...
View ArticleSCG Cell Therapy gets China thumbs-up for study of potentially curative HBV...
A Singaporean biotech said it has the green light to start a Phase 1/2 trial of a cell therapy designed to cure chronic hepatitis B infection in what it claims is an industry first. ...
View Article